Evidence-to-translation matrix of nutrition–microbiota–host pathways.
| Biological axis | Evidence strength | Causal confidence | Human translation | Major confounders | Current evidence supports | Key evidence gap |
|---|---|---|---|---|---|---|
| Dietary patterns and microbiota function [2, 6, 9, 15, 17, 20, 24, 50] | Moderate–strong | Moderate for microbiota changes; low–moderate for metabolic effects | Moderate | Baseline microbiota, habitual diet, medications, lifestyle | Dietary patterns can modify microbial composition and function in a context-dependent manner. | Functional microbial features that reliably predict metabolic benefit. |
| Microbial metabolites and host metabolism [34–39, 42] | Strong mechanistic; moderate human | Moderate for selected pathways; limited for disease progression | Moderate | Substrate availability, microbial capacity, tissue exposure, host phenotype | Microbial metabolites can modulate host metabolic and immune pathways. | Reproducible, clinically meaningful effects in humans. |
| Microbial metabolites and oxidative balance [45, 48, 49] | Moderate mechanistic | Low–moderate in humans | Limited–moderate | Tissue exposure, redox state, metabolic context, experimental model | Microbial metabolites can influence redox regulation and cellular oxidative balance. | Whether these effects translate into sustained metabolic benefit. |
| Proteostasis and metabolic resilience [44, 46, 47, 49] | Moderate mechanistic | Low | Limited | Disease stage, tissue specificity, cellular stress context | Oxidative and cellular stress can disrupt protein quality control and proteostasis. | Whether proteostatic dysfunction precedes metabolic dysfunction and can be modified. |
| Oxidative stress and inflammation [51–53, 60–65] | Strong biological and experimental | Moderate for interaction; low for temporal direction | Moderate | Adiposity, tissue context, disease stage, comorbidities | Oxidative and inflammatory pathways interact in metabolic dysfunction. | Directionality of the relationship and its therapeutic relevance. |
| Dietary patterns and inflammatory signaling [51–53, 56, 57] | Moderate observational/intervention | Low–moderate | Moderate | Energy balance, adiposity, microbiota, physical activity, medications | Dietary patterns can modify inflammatory profiles. | Whether specific inflammatory changes mediate metabolic benefit. |
| Microbiota and inflammatory signaling [58–65] | Moderate mechanistic | Low–moderate in humans | Limited–moderate | Barrier integrity, microbial ecology, tissue context, disease stage | Microbial activity and metabolites can influence barrier and immune signaling associated with metabolic inflammation. | Whether these changes causally contribute to metabolic dysfunction in humans. |
| Multi-omics and individualized response [67–73, 75, 77–79] | Emerging–moderate | Low–moderate | Limited | Cohort composition, analytical pipelines, batch effects, model overfitting, population heterogeneity | Multi-omics profiling can characterize heterogeneity in dietary and metabolic responses. | Reproducible predictive signatures across populations and interventions. |
| Biomarkers and intervention selection [72–80] | Emerging | Low without prospective validation | Limited | Confounding, reverse causality, measurement variability | Candidate biomarkers can characterize dietary response and metabolic state. | Predictive value and benefit beyond established dietary approaches. |
The matrix summarizes evidence strength, causal confidence, and translational maturity across dietary, microbial, metabolic, inflammatory, and precision-nutrition pathways. Evidence is generally stronger for associations and mechanistic plausibility than for causality or clinical translation. Interpretation is constrained by host and environmental heterogeneity, methodological variation, tissue specificity, reverse causality, and limited longitudinal intervention data.